GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, announced today that they will present at the Sickle Cell Disease Association of America (SCDAA) 40th Annual Convention. The convention, designed to address the multi-factorial aspects of sickle cell disease through an exchange of the latest scientific and clinical information, will be held September 25-28, 2012, at the Baltimore Marriott Waterfront in Baltimore, Maryland.
